10 Mar 2015 14:56
10 March 2015
Β
Collagen Solutions Plc
(the "Company" or the "Group")
Β
Director/PDMR Shareholding
Β
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to announce that Mr. David E Evans, Chairman of the Company, has today purchased 250,000 ordinary shares in the Company at 8.65p per share.
Β
Following this transaction, Mr. Evans total beneficial holding has increased to 12,888,730 ordinary shares representing 7.54 per cent of the issued ordinary share capital of the Company.
Β
Β
Enquiries:
Β
Collagen Solutions Plc | Β |
David Evans, ChairmanΒ | Tel: 07740 084 452 |
Stewart White, CEO | Tel: 0141 558 2008 |
Β | Β |
Zeus Capital (Nominated Adviser and Broker) | Β |
Ross Andrews / John Depasquale | Tel: 020 7533 7727 |
Alex Davies Β Panmure Gordon & Co (Joint Broker) | Β |
Robert Naylor (Corporate Finance) Maisie Atkinson (Corporate Broking) | Tel: 020 7886 2714Tel: 020 7886 2905 |
Β | Β |
Walbrook PR Ltd | Tel: 020 7933 8780 or collagen@walbrookpr.com |
Mike Wort | Mob: 07900 608 002 |
Anna Dunphy | Mob: 07876 741 001 |
Β
Β
Follow the stocks